MX2017013206A - Secuencia de nucleotidos optimizada y composicion farmaceutica basada en la misma con expresion de transgen vegf prolongada. - Google Patents
Secuencia de nucleotidos optimizada y composicion farmaceutica basada en la misma con expresion de transgen vegf prolongada.Info
- Publication number
- MX2017013206A MX2017013206A MX2017013206A MX2017013206A MX2017013206A MX 2017013206 A MX2017013206 A MX 2017013206A MX 2017013206 A MX2017013206 A MX 2017013206A MX 2017013206 A MX2017013206 A MX 2017013206A MX 2017013206 A MX2017013206 A MX 2017013206A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- nucleotide sequence
- composition based
- transgene expression
- optimized nucleotide
- Prior art date
Links
- 239000002773 nucleotide Substances 0.000 title abstract 2
- 125000003729 nucleotide group Chemical group 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 108700019146 Transgenes Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 230000002035 prolonged effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 108020004999 messenger RNA Proteins 0.000 abstract 2
- 108020005345 3' Untranslated Regions Proteins 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se han identificado cambios puntuales a la secuencia de nucleótidos 3´UTR del gen VEGF que incrementan significativamente el lapso de vida del producto de transcripción de mRNA del gen en las células de mamífero. Un constructo de gen con una lista óptima de las mutaciones identificadas, que se caracteriza por un lapso de vida de mRNA máximo, se ha seleccionado por experimentación. El efecto biológico del constructo de gen desarrollado y de una composición farmacéutica en base al mismo se ha confirmado in vitro e in vivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2015119768A RU2612497C2 (ru) | 2015-05-26 | 2015-05-26 | Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf |
| PCT/RU2015/000852 WO2016190774A1 (ru) | 2015-05-26 | 2015-12-07 | Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013206A true MX2017013206A (es) | 2018-02-15 |
Family
ID=57392933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013206A MX2017013206A (es) | 2015-05-26 | 2015-12-07 | Secuencia de nucleotidos optimizada y composicion farmaceutica basada en la misma con expresion de transgen vegf prolongada. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9896493B2 (es) |
| EP (1) | EP3305901B1 (es) |
| CN (1) | CN107614687B (es) |
| AU (1) | AU2015396177B2 (es) |
| BR (1) | BR112017023058B1 (es) |
| CA (1) | CA2985608C (es) |
| EA (1) | EA039395B1 (es) |
| MX (1) | MX2017013206A (es) |
| RU (1) | RU2612497C2 (es) |
| WO (1) | WO2016190774A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114908089B (zh) * | 2021-02-08 | 2024-03-15 | 上海细胞治疗集团有限公司 | 3’utr的构建方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
| US5587300A (en) * | 1994-04-26 | 1996-12-24 | Wisconsin Ulumni Research Foundation | Method to increase regulatory molecule production |
| US6613563B1 (en) | 1997-03-14 | 2003-09-02 | Selective Gentics, Inc. | Viral vectors with modified tropism |
| US6627436B2 (en) | 1997-10-31 | 2003-09-30 | Stratagene | Vector for gene expression in prokaryotic and eukaryotic systems |
| ES2239440T3 (es) | 1998-03-13 | 2005-09-16 | Wyeth | Composicion polinucleotidica, procedimiento para la preparacion y utilizacion de la misma. |
| US7598079B2 (en) * | 1998-12-24 | 2009-10-06 | Novation Pharmaceuticals, Inc. | Assay for identifying compounds which affect stability of mRNA |
| WO2000047235A2 (en) | 1999-02-10 | 2000-08-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of stimulating angiogenesis |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7288521B2 (en) | 2000-04-06 | 2007-10-30 | Franco Wayne P | Growth factor therapy mobilization of stem cells into the peripheral blood |
| CN1351055A (zh) | 2000-10-26 | 2002-05-29 | 上海博德基因开发有限公司 | 一种新的多肽——人的血管内皮生长因子165受体(vegf－165r)10.67和编码这种多肽的多核苷酸 |
| EP1581241A4 (en) * | 2001-06-20 | 2005-11-09 | Ludwig Inst Cancer Res | STIMULATION OF VASCULARIZATION WITH VEGF-B |
| US7981863B2 (en) | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
| CN100431611C (zh) | 2002-07-04 | 2008-11-12 | 朱静亚 | 多肽－脂质体与人血管内皮生长因子基因重组质粒复合物及用途 |
| AU2003302590B2 (en) | 2002-12-02 | 2008-11-06 | Anges Mg, Inc. | Compositions for treating or preventing angiogenesis-dependent symptoms |
| WO2006029908A1 (en) | 2004-09-17 | 2006-03-23 | Centelion | Stable liquid formulations of plasmid dna |
| RU2297848C2 (ru) | 2005-05-11 | 2007-04-27 | Александр Веньяминович Иткес | Генно-инженерная конструкция vegf-ибмед (vegf-ibmed) |
| ES2338400B1 (es) | 2008-05-06 | 2011-09-14 | David Benet Ferrus | Conjunto de moleculas antiangiogenicas y su uso. |
| SG174150A1 (en) | 2009-02-24 | 2011-10-28 | Scripps Research Inst | Reengineering mrna primary structure for enhanced protein production |
| US8367350B2 (en) | 2009-04-29 | 2013-02-05 | Morehouse School Of Medicine | Compositions and methods for diagnosis, prognosis and management of malaria |
| RU2431669C2 (ru) * | 2009-06-23 | 2011-10-20 | Государственное образовательное учреждение высшего профессионального образования "Казанский государственный университет им. В.И. Ульянова-Ленина" | Способ получения лекарственного препарата генетически модифицированных клеток |
| RU2542385C2 (ru) | 2012-08-31 | 2015-02-20 | Общество с ограниченной ответственностью "НекстГен" | Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека |
-
2015
- 2015-05-26 RU RU2015119768A patent/RU2612497C2/ru active
- 2015-12-07 EA EA201700456A patent/EA039395B1/ru unknown
- 2015-12-07 BR BR112017023058-5A patent/BR112017023058B1/pt active IP Right Grant
- 2015-12-07 WO PCT/RU2015/000852 patent/WO2016190774A1/ru not_active Ceased
- 2015-12-07 AU AU2015396177A patent/AU2015396177B2/en active Active
- 2015-12-07 MX MX2017013206A patent/MX2017013206A/es unknown
- 2015-12-07 CA CA2985608A patent/CA2985608C/en active Active
- 2015-12-07 EP EP15893474.5A patent/EP3305901B1/en active Active
- 2015-12-07 CN CN201580080399.1A patent/CN107614687B/zh active Active
-
2016
- 2016-03-15 US US15/070,239 patent/US9896493B2/en active Active
-
2017
- 2017-11-21 US US15/819,157 patent/US10040837B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017023058B1 (pt) | 2024-03-05 |
| US9896493B2 (en) | 2018-02-20 |
| AU2015396177B2 (en) | 2019-02-28 |
| US20160347803A1 (en) | 2016-12-01 |
| EP3305901B1 (en) | 2020-09-30 |
| CN107614687A (zh) | 2018-01-19 |
| US10040837B2 (en) | 2018-08-07 |
| AU2015396177A1 (en) | 2017-11-02 |
| EP3305901A1 (en) | 2018-04-11 |
| WO2016190774A1 (ru) | 2016-12-01 |
| BR112017023058A2 (pt) | 2018-10-16 |
| CA2985608A1 (en) | 2016-12-01 |
| RU2015119768A (ru) | 2016-12-20 |
| CN107614687B (zh) | 2021-05-28 |
| CA2985608C (en) | 2021-06-15 |
| US20180086800A1 (en) | 2018-03-29 |
| EP3305901A4 (en) | 2018-10-24 |
| RU2612497C2 (ru) | 2017-03-09 |
| EA201700456A1 (ru) | 2018-06-29 |
| EA039395B1 (ru) | 2022-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3728596A4 (en) | CONSTRUCTION OF NUCLEIC ACID ALLOWING THE EXPRESSION OF A GENE IN VITRO AND IN VIVO | |
| ECSP19017082A (es) | Regulación de la expresión génica usando nucleasas modificadas | |
| CA2851316C (en) | Genes and proteins for alkanoyl-coa synthesis | |
| PH12019501262A1 (en) | Modified guide rnas | |
| AR092317A1 (es) | Vectores virales para el tratamiento de distrofia retiniana | |
| MX2021005226A (es) | Regulacion de expresion genica mediada por nucleasa. | |
| BR112016025519A2 (pt) | engenharia genética in vivo com vetores de adenovírus | |
| MX2013003681A (es) | Ácidos nucleicos manipulados y métodos de uso de los mismos. | |
| PH12015500213A1 (en) | Production of fmdv-resistant livestock by allele substitution | |
| MX2018010529A (es) | Composiciones y metodos para la produccion y administracion de acido ribonucleico. | |
| EA201692318A1 (ru) | Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина | |
| MX387332B (es) | Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo. | |
| WO2013060819A3 (en) | Transient expression vectors, preparation and uses thereof | |
| WO2014118817A3 (en) | Platelets transfected by exogenous genetic material and platelet microparticles obtained by said transfected platelets, method for the preparation and uses thereof | |
| MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
| IL276424A (en) | A special promoter for oligodendrocytes, a special mirna for the plp1 gene, a vector including the above-mentioned promoter and/or mirna, and a pharmaceutical composition including the above-mentioned vector | |
| IN2014DN10111A (es) | ||
| MX382997B (es) | Composiciones y metodos para mejorar la expresion genetica de pklr. | |
| MX2017013206A (es) | Secuencia de nucleotidos optimizada y composicion farmaceutica basada en la misma con expresion de transgen vegf prolongada. | |
| MX2016013363A (es) | Metodo para aumentar la capacidad de sintesis de biomasa de microorganismos y microorganismos modificados a partir de ellos. | |
| BR112017000940A2 (pt) | modificação genética de bactérias termofílicas produzindo ácido (s)-lático | |
| Swarr et al. | A105 NEONATAL LUNG DISEASE: HYPEROXIA-INDUCED LUNG INJURY AND BRONCHOPULMONARY DYSPLASIA: Comprehensive Analysis Of The Lung Transcriptome Reveals Multiple Long Noncoding Rnas (lncrnas) Involved In Lung Development And Differentiation | |
| AR110625A1 (es) | Regulación de la expresión de genes utilizando nucleasas modificadas por ingeniería genética | |
| Skrotska et al. | THE CYTOTOXIC EFFECT OF THE DRUG IZATIZON ON THE CULTURE OF НЕК-293 | |
| RU2012105584A (ru) | Создание интегративной генетической конструкции для экспрессии гена релизинг фактора гормона роста в бактериях |